Buy Crispr

Logo for stock CRSP (Crispr)

Amount

£
GBP

Latest price

$42.07
(£1.00 = $1.295)

Number of shares (est.)

0

Start investing today

Open an investment account in Emma and enjoy commission free stock trading. Capital at risk, other charges apply.

QR code linking to downloads for the Emma app.
Download on the App Store buttonGet it on Google Play button

Metrics

Market Cap

$3.602B

P/E ratio

-9.67

EPS

-$4.342

Beta

1.75

Dividend rate

N/A

Dividend yield

N/A

About

CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

CEO

Dr. Samarth Kulkarni, Ph.D.

Employees

393

Sector

Health

Company HQ

ZUG, Switzerland

News

Logo for news article #0 (CRISPR Therapeutics AG (CRSP) TD Cowen 45th Annual Healthcare Conference (Transcript))

CRISPR Therapeutics AG (CRSP) TD Cowen 45th Annual Healthcare Conference (Transcript)

CRISPR Therapeutics AG (NASDAQ:CRSP ) TD Cowen 45th Annual Healthcare Conference March 3, 2025 10:30 AM ET Company Participants Samarth Kulkarni - CEO Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren Good morning, everyone. Welcome again to TD Cowen's 45th Annual Healthcare Conference, our first day.

Seeking Alpha

March 03, 2025

Logo for news article #1 (CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know)

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks Investment Research

March 03, 2025

Logo for news article #2 (Prediction: CRISPR Therapeutics Will Beat the Market. Here's Why)

Prediction: CRISPR Therapeutics Will Beat the Market. Here's Why

Explore the exciting world of CRISPR Therapeutics (CRSP 0.69%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

The Motley Fool

March 01, 2025

Emma logo
Facebook logoTiktok logoTwitter / X logoInstagram logo

© 2025 Emma Technologies Ltd. All Rights Reserved.

Emma is registered and incorporated in England and Wales.

Emma Technologies Ltd is an appointed representative of RiskSave Technologies Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN 775330).

Payment services (Non MIFID or Deposit related products) for Emma Technologies Ltd are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN: 900199). For more detail on how your money is protected please see here. You can also find Currency Cloud's Terms of Use here.

Emma Technologies Ltd is an Introducer Appointed Representative of Quint Group Limited, which is authorised and regulated by the Financial Conduct Authority (FRN 669450). Emma Technologies Ltd is not a lender. Emma Technologies Ltd introduces customers to Monevo Limited who is a licensed credit broker.

Emma is registered with the Financial Conduct Authority under the Payment Services Regulations 2017 for the provision of payment services.

Financial Conduct Authority Reg Nr: 794952.
Company Registration Number: 10578464.
Data Protection Registration Number: ZA241546.

All testimonials, reviews, opinions or case studies presented on our website may not be indicative of all customers. Results may vary and customers agree to proceed at their own risk.